Skip to content

Released Feb 14, 2023, after the close

10-K filed Mar 14, 2023, 73 days after period end · 0001162194-23-000013

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$27.02Mderived−29.4% vs Q4 2021+5.4% vs Q3 2022
Net Income-$20.85MderivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$21,112,000N/M
Operating Cash Flowderived-$19,181,000N/M
Free Cash Flowderived-$19,936,000N/M
Margins · derived
Operating margin-78.1%−48.7 pt vs Q4 2021
Net margin-77.1%−52.5 pt vs Q4 2021

What the release said

The release

Same quarter

MetricQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020Q4 2019
Revenue$27.02M$38.27M$44.61M$32.44M
Net Income-$20.85M-$9.43M-$18.03M-$12.69M
EPS Diluted——-$0.24-$0.18

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR